Biotech Stocks At 52-Week Highs - NEO, BLSM, RVMD, ORMP, CADL
NeoGenomics (NEO), BlossomHill Therapeutics (BLSM), Revolution Medicines (RVMD), Oramed Pharmaceuticals (ORMP), and Candel Therapeutics (CADL) reached 52-week highs on August 27, 2026. NEO reported Q2 revenue growth of 11% and a profit turnaround. BLSM began trading on Nasdaq and received FDA Fast Track designation. RVMD's lead drug, Rasonque, was FDA-approved. ORMP's net income increased significantly. CADL reported a higher net loss but plans a BLA filing for its lead drug.
How this was made
The 30-second read
Why it matters
Collective regulatory approvals and fast‑track designations create a sector‑wide bullish bias, but individual company fundamentals vary.
Market read
Multiple fresh regulatory and earnings events drive a short‑term rally across the biotech space.
What to watch
Potential reimbursement limitations for NeoGenomics and competitive pipeline risks for Revolution Medicines.
Background
The article aggregates several biotech companies that hit 52‑week highs on August 27, 2026, each driven by distinct regulatory or earnings catalysts.
Ticker impact
NeoGenomics announced Medicare and Medicaid coverage for its RaDaR ST test, driving a 7% share rise to a 52‑week high.
Short‑term upside as coverage expands market adoption.
Coverage approval is a fresh catalyst with immediate pricing impact.
Blossom Hill received FDA Fast Track designation for BH‑30643, sending the stock up over 7% to a 52‑week high.
Continued rally expected pending trial data.
Fast Track is a material regulatory milestone disclosed today.
The FDA approved Revolution Medicines' lead drug Rasonque (Daraxonrasib), lifting the stock 2% to $224.31.
Potential upside as the drug launches and sales ramp.
FDA approval is a primary, high‑impact disclosure.
Oramed posted a net income rise to $78.16 M, helping the stock reach a 52‑week high of $5.47.
Likely modest upside if earnings trend continues.
Earnings beat is fresh but less material than regulatory events.
Candel Therapeutics released Q2 results showing a larger net loss, yet the stock rose 3% to a 52‑week high of $14.
Short‑term rally may persist pending BLA filing.
Result release is new information but impact is mixed.
Market effects
Biotech sector gains momentum as multiple companies receive regulatory approvals and designations.
U.S. biotech equities see broad uplift, influencing Nasdaq biotech indices.
Positive US biotech news may lift global biotech ETFs and related foreign listings.
Counterpoint
Rapid price spikes may be speculative; investors should assess cash burn and execution risk.
Key entities
- companyNeoGenomics Inc.
Diagnostics firm receiving Medicare/Medicaid coverage.
- companyBlossom Hill Therapeutics Inc.
Biopharma with FDA Fast Track for BH‑30643.
- companyRevolution Medicines Inc.
Oncology company with FDA‑approved Rasonque.
- companyOramed Pharmaceuticals Inc.
Biotech reporting higher net income.
- companyCandel Therapeutics Inc.
Biopharma preparing BLA filing.
